Ricerca forms strategic alliance with Sumika Fine Chemicals
US drug development and contract research services company Ricerca has formed a strategic partnership with Sumika Fine Chemicals, a leading Japanese pharmaceutical fine chemical custom manufacturing company based in Osaka.
The two companies will collaborate on and offer Active Pharmaceutical Ingredients (APIs), chemical process development, and scale-up and commercial manufacturing capacity to biotechnology and pharmaceutical companies.
The agreement, which is renewable after the initial three-year term, says that Ricerca will provide process chemistry, development, scale-up and API production services through Phase II of the clinical development programme for its clients' projects. These projects may then be transferred to Sumika Fine Chemicals for Phase III clinical trials and commercial API manufacture.
'Ricerca can now provide its clients with development capabilities ranging from discovery target validation to lead optimisation and IND packages to commercial API manufacture with choice of production sites in Europe, the US and Sumika's three world-class facilities in Japan,' said Dr John R. Peterson, Ricerca's vice president of corporate development.
This latest agreement follows the formation in February of a similar alliance with Siegfried, an integrated pharmaceutical manufacturing and service company, based in Zofingen, Switzerland.
Earlier this year Ricerca also established a three-year, renewable international partnership in small-molecule drug discovery and development with Indian biotechnology company gvk bioSciences, giving Ricerca exclusive worldwide access to gvk's medicinal chemistry services in return for providing gvk bioSciences with some of its proprietary drug targets or early hits for joint drug development.
The Indian company will build a new facility located in Hyderabad to carry out medicinal chemistry and biology under Ricerca's direction for client drug discovery programmes and proprietary lead optimisation of each company's own drug targets.